Source: MHRA 11.6.26
Having met the MHRA’s rigorous standards of safety, quality and effectiveness, the semaglutide tablet has been approved in the UK for weight loss and weight management.
The UK’s first GLP-1 receptor agonist tablet for weight loss and weight management has today (11 June 2026) been approved by the Medicines and Healthcare products Regulatory Agency (MHRA).
Alongside a reduced-calorie diet and increased physical activity, the semaglutide (Wegovy) tablet may now be prescribed to adults in the UK with obesity, who have a Body Mass Index (BMI) of 30 or above, or who are overweight with a BMI between 27 and 30 and at least one weight-related comorbidity.
The starting dose for the semaglutide tablet is 1.5 mg once daily, increasing to 4 mg, 9 mg and 25 mg with a minimum duration of one month at each dose level.
Patients currently treated privately with a 2.4 mg semaglutide injection once weekly can be transitioned straight to semaglutide 25 mg tablets once daily.
Click here for the source.
